

General Information

Name: Prof. Dr. med. Konstanze Döhner
Date of Birth: 13.10.1964
Gender: Female
Address: Department of Internal Medicine III, Ulm University Hospital
Albert-Einstein-Allee 23, 89081 Ulm, Germany
Phone: +49 731 500 45543
E-Mail: konstanze.doehner@uniklinik-ulm.de
Current Positions: Attending Physician, Department of Internal Medicine III
Head, Laboratory Program in Myeloid Malignancies

Academic Education

1984-1991 University of Heidelberg Medical School, Heidelberg, Germany

Academic Degrees

2005 Professor (*Außerplanmäßige Professorin [apl.]*), Ulm University, Ulm
Germany
2001 Postdoctoral Thesis (*Habilitation*), Internal Medicine, University of
Heidelberg, Germany
1992 Doctoral Thesis (*Dr. med.*), University of Heidelberg, Medical School,
Heidelberg, Germany

Professional Experience

Since April 2000 Oberarzt (Consultant), Department of Hematology, Oncology, Palliative
Medicine, Rheumatology and Infectious Diseases, (Director: Prof. H.
Döhner), Ulm University Hospital, Ulm, Germany
Since 1999 Head, Cytogenetics and Genetics Laboratory at the Department of
Internal Medicine III, Ulm University
1995-1997 Postdoctoral Associate at the German Cancer Research Center (Prof.
Dr. Peter Lichter) in Heidelberg, Germany, and the Hospital for Sick
Children, Department of Genetics (Dr. S.W. Scherer) Toronto, Canada
1992-1999 Training in Internal Medicine Hematology / Oncology / Rheumatology,
Medizinische Klinik and Poliklinik V (Prof. W. Hunstein), University of
Heidelberg, Germany
1991-1992 Residency in Internal Medicine Hematology / Oncology /
Rheumatology, Medizinische Klinik and Poliklinik V (Prof. W. Hunstein),
University of Heidelberg, Germany

Miscellaneous

Awards

2006 Science Award of the City of Ulm
1998 Research Award of the Süddeutsche Hämoblastosengruppe e.V., 1998

Committees

Since 2018 Elected Member, Board of the European Hematology Association
(EHA)
2016-2019 Elected Member, Myeloid Neoplasia Committee, American 'Society of
Hematology'
Since 2011 Member, Fachausschuss "Medizinisch / Wissenschaftliche
Nachwuchsförderung", Deutsche Krebshilfe

Publications

1. Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Horst HA, Koller E, Wulf G, Schleicher J, Bentz M, Greil R, Hertenstein B, Krauter J, Martens U, Nachbaur D, Samra MA, Girschikofsky M, Basara N, Benner A, Thol F, Heuser M, Ganser A, Döhner K, Döhner H. Gemtuzumab ozogamicin in NPM1-mutated AML: Results from the prospective randomized AMLSG 09-09 phase-III study. **J Clin Oncol**. 2019, accepted for publication.
2. Döhner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA, Prior TW, Marcucci G,⁵ Jones D, Krauter J, Heuser M, Voso MT, Ottone T, Nomdedeu JF, Mandrekar S, Klisovic RB, Wei AH, Sierra J, Sanz M, Brandwein JM, de Witte T, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Gathmann I, Benner A, Pallaud C, Stone RM, Döhner H, Bloomfield CD. Impact of *NPM1/FLT3*-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. **Blood**. 2019, accepted for publication. *Equal contribution
3. Cocciardi S, Dolnik A, Kapp-Schwoerer S, Rucker FG, Lux S, Blätte TJ, Skambraks S, Krönke J, Heidel FH, Schnöder TM, Corbacioglu A, Gaidzik VI, Paschka P, Teleanu V, Göhring G, Thol F, Heuser M, Ganser A, Weber D, Sträng E, Kestler HA, Döhner H, Bullinger L*, Döhner K*. Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. **Nat Commun**. 2019;10(1):2031. *Equal contribution
4. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H. Midostaurin plus Chemotherapy for Acute Leukemia with a FLT3 Mutation. **N Engl J Med**. 2017;377(5):454-64.
5. Papaemmanuil E*, Gerstung M*, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Döhner K, Schlenk RF, Döhner H*, Campbell PJ*. [Genomic Classification and Prognosis in Acute Myeloid Leukemia](#). **N Engl J Med**. 2016;374:2209-21. *Equal contribution
6. Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, Held G, Brossart P, Lübbert M, Salih HR, Kindler T, Horst HA, Wulf G, Nachbaur D, Götze K, Lamparter A, Paschka P, Gaidzik VI, Teleanu V, Späth D, Benner A, Krauter J, Ganser A, Döhner H, Döhner K; German-Austrian AML Study Group. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. **Blood**. 2014;124(23):3441-9.
7. Krönke J, Bullinger L, Teleanu V, Tschürtz F, Gaidzik VI, Kühn MW, Rucker FG, Holzmann K, Paschka P, Kapp-Schwörer S, Späth D, Kindler T, Schittenhelm M, Krauter J, Ganser A, Göhring G, Schlegelberger B, Schlenk RF, Döhner H, Döhner K. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. **Blood**. 2013;122(1):100-8.
8. Krönke J, Schlenk RF, Jensen KO, Tschürtz F, Corbacioglu A, Gaidzik VI, Paschka P, Onken S, Eiwien K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih HR, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler HG, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K. Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia: A study of the German-Austrian AML Study Group (AMLSG). **J Clin Oncol**. 2011;29(19):2709-16.
9. Paschka P, Schlenk R.F, Gaidzik V.I, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst H-A, Germing U, Döhner H, Döhner K. IDH1 and IDH2 Mutations are Frequent Genetic Alterations in Acute Myeloid Leukemia (AML) and Confer Adverse Prognosis in Cytogenetically Normal AML with NPM1 Mutation without FLT3-ITD. **J Clin Oncol** 2010;28(22):3636-43.
10. Schlenk RF*, Döhner K*, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H for the German-Austrian AML Study Group (AMLSG). Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.. **N Engl J Med** 2008;358(18):1909-18. *Equal contribution.